نوع مقاله : Original Article(s)
نویسندگان
1 استادیار، گروه نفرولوژی، مرکز تحقیقات بیماریهای کلیه، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
2 دانشیار، گروه نفرولوژی، مرکز تحقیقات بیماریهای کلیه، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
3 دانشجوی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
4 رزیدنت داخلی، دانشکده پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
5 گروه آمار، مرکز تحقیقات بیماریهای کلیه، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
چکیده
کلیدواژهها
عنوان مقاله [English]
نویسندگان [English]
Background: Anemia is one of the major problems of dialysis patients The primary mechanism of anemia in these patients is Erythropoietin insufficient production by kidneys. Often, this kind of anemia is caused by inflammatory reactions. A large number of dialysis patients, despite receiving adequate doses of erythropoietin, are anemic. Therefore it seems the use of a pharmaceutical composition that can control the inflammatory reactions is an appropriate strategy. This study was done to investigate the effect of Pentoxyfilline on hemoglobin level and Erythropoietin dose in these patientsMethods: This study was a clinical trial that performed on anemic peritoneal dialysis patients. Study patients were randomized to two groups of 25 person recipients Pentoxyfilline and control groups. The amount of blood hemoglobin and serum albumin, iron, Total Iron Binding Capacity (TIBC), ferritin and Parathormone (PTH) were measured at the beginning and the end of the study. Collected data were analyzed by SPSS software.Finding: 45 patients were studied (20 cases and 25 controls). The results of this study have not shown the significant differences in hemoglobin and serum albumin levels changes between two groups. According to results of this study the change of erythropoietin dose was not significant in both goups.Conclusions: According to the results, conducted another study with higher sample size and longer time for investigation of the effect Pentoxyfilline is recommended.
کلیدواژهها [English]